NasdaqGM - Nasdaq Real Time Price USD

Actuate Therapeutics, Inc. Common stock (ACTU)

10.98
+0.38
+(3.58%)
At close: May 21 at 4:00:01 PM EDT
10.98
0.00
(0.00%)
After hours: May 21 at 4:04:13 PM EDT
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for ACTU

Recent News: ACTU

View More
Actuate Therapeutics to Host KOL Event on Topline Phase 2 Data of Elraglusib in Metastatic Pancreatic Ductal Adenocarcinoma During ASCO Annual Meeting

Actuate Therapeutics to Host KOL Event on Topline Phase 2 Data of Elraglusib in Metastatic Pancreatic Ductal Adenocarcinoma During ASCO Annual Meeting
GlobeNewswire 14 days ago
Actuate Therapeutics Announces Statistically Significant Topline Results from Global Phase 2 Trial of Elraglusib in First-Line Treatment of Metastatic Pancreatic Cancer

Actuate Therapeutics Announces Statistically Significant Topline Results from Global Phase 2 Trial of Elraglusib in First-Line Treatment of Metastatic Pancreatic Cancer
GlobeNewswire 15 days ago
Actuate Therapeutics to Participate in Citizens Life Sciences Conference 2025

Actuate Therapeutics to Participate in Citizens Life Sciences Conference 2025
GlobeNewswire 21 days ago
Actuate to Present Elraglusib Phase 2 Topline Data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Actuate to Present Elraglusib Phase 2 Topline Data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewswire 28 days ago
Actuate to Present Promising Data on Elraglusib in Advanced Salivary Gland Carcinoma at the AACR Annual Meeting 2025

Actuate to Present Promising Data on Elraglusib in Advanced Salivary Gland Carcinoma at the AACR Annual Meeting 2025
GlobeNewswire last month
Actuate Announces Completion of Enrollment in a Phase 2 Trial of Elraglusib in Combination with FOLFIRINOX and Losartan in Patients with Previously Untreated Metastatic Pancreatic Cancer

Actuate Announces Completion of Enrollment in a Phase 2 Trial of Elraglusib in Combination with FOLFIRINOX and Losartan in Patients with Previously Untreated Metastatic Pancreatic Cancer
GlobeNewswire 2 months ago
Is Actuate Therapeutics (NASDAQ:ACTU) In A Good Position To Deliver On Growth Plans?

Is Actuate Therapeutics (NASDAQ:ACTU) In A Good Position To Deliver On Growth Plans?
Simply Wall St. 3 months ago
Actuate Therapeutics to Participate in Upcoming Investor Conferences in February

Actuate Therapeutics to Participate in Upcoming Investor Conferences in February
GlobeNewswire 3 months ago
Actuate Therapeutics Receives EMA Orphan Medicinal Product Designation for Elraglusib for the Treatment of Pancreatic Cancer

Actuate Therapeutics Receives EMA Orphan Medicinal Product Designation for Elraglusib for the Treatment of Pancreatic Cancer
GlobeNewswire 4 months ago
Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer

Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer
GlobeNewswire 5 months ago
Actuate Therapeutics to be Added to Russell 2000® Index

Actuate Therapeutics to be Added to Russell 2000® Index
GlobeNewswire 5 months ago
View More

Related Tickers

RNTX Rein Therapeutics Inc.
1.9400
+0.52%
 
COYA Coya Therapeutics, Inc.
5.67
-3.24%
 
CUE Cue Biopharma, Inc.
0.6012
-10.22%
 
INAB IN8bio, Inc.
0.1260
-3.08%
 
APTOF Aptose Biosciences Inc.
1.6800
-5.62%
 
RNXT RenovoRx, Inc.
1.2200
0.00%
 
GNTA Genenta Science S.p.A.
4.1400
-3.72%
 
APS.TO Aptose Biosciences Inc.
2.4000
+1.27%
 
LTRN Lantern Pharma Inc.
3.3400
-4.02%
 
DSGN Design Therapeutics, Inc.
3.6000
-1.91%